Close menu




August 2nd, 2022 | 10:57 CEST

Defence Therapeutics VP Research + Development Dr. Moutih Rafei on the next generation oncology-targeting therapies

  • Expert
  • Biotech
  • Cancer
  • DefenceTherapeutics
Photo credits: pixabay.com

The publicly traded biotechnology company called Defence Therapeutics is developing new vaccines and ADC products on its own proprietary platform. The Accum technology, which enables precise delivery of vaccine antigens or ADCs in their intact form to target cells, forms the basis of Defence Therapeutics' platform. As a result, catastrophic illnesses like cancer and infectious diseases can be combated with greater efficacy and potency.

time to read: 1 minutes | Author: Mario Hose
ISIN: DEFENCE THERAPEUTICS INC | CA24463V1013

Table of contents:


    Sébastien Plouffe, CEO and Director, Defence Therapeutics
    "[...] Accum™ helps us target active ingredients precisely to the origin of infections or diseases. [...]" Sébastien Plouffe, CEO and Director, Defence Therapeutics

    Full interview

     

    Cancer is one of the most common causes of death and those affected often have a long journey of suffering. What progress can Defence Therapeutics show in the field of fighting the disease?

    'Cancer is a multifactorial disease caused by mutations accumulated through years. Therefore, targeting cancer through a specific pathway may not lead to the hoped-for outcome.

    Defence is working on the development of the next generation oncology-targeting therapies. Most of its arsenal is based on the use of the Accum technology, which consists of empowering biomedicine's accumulation into target cells via endosomal escape.

    As such, the company has developed antibody-drug conjugates, anti-cancer small molecules and protein- or cell-based anti-cancer vaccine formulations. Multiple Phase I trials using some of these products are expected to start in Q1/Q2 of 2023.'

    Dr. Moutih Rafei, VP Research & Development, Defence Therapeutics Inc.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Mario Hose

    Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

    About the author



    Related comments:

    Commented by André Will-Laudien on September 29th, 2025 | 07:20 CEST

    Attention: Acquisitions! Biotechs like Evotec, PanGenomic Health, Pfizer, and BioNTech in focus

    • Biotechnology
    • Biotech
    • Healthcare
    • healthtech

    The biotech industry is in turmoil! With the expiration of blockbuster patents, there is a threat of sharp declines in revenue, which must be strategically compensated for. Driven by economic pressure and a growing focus on innovation and technology, the industry is increasingly turning to acquisitions of biotech companies with promising drug candidates, new technologies, and digital expertise. Not only are entire pipelines being acquired, but key players from the fastest-growing segments are also being targeted, particularly in the field of obesity therapies, where billions are being paid for drug candidates. Several examples illustrate this wave of transformation. Companies are restructuring, focusing their activities, and rapidly preparing for a phase of sustainable growth. The pace is picking up! Here are some promising investment ideas!

    Read

    Commented by Fabian Lorenz on September 29th, 2025 | 07:00 CEST

    Takeover in the Ozempic market! BioNxt Solutions next? Novo Nordisk, Eli Lilly, and Pfizer are fighting!

    • Biotechnology
    • Biotech
    • Pharma

    The battle against obesity is considered one of the biggest growth markets in the global pharmaceutical sector. According to estimates, the market for obesity therapies could reach a volume of up to USD 150 billion by 2030. So far, Novo Nordisk and Eli Lilly have dominated the market. But almost every major corporation and innovative challenger wants a piece of the pie. The latest example: Pfizer is planning a billion-dollar takeover of US-based Metsera, a company competing with novel drugs against obesity. BioNxt Solutions is also a hot takeover candidate. The Company aims to revolutionize the market and attract new customers with an oral dosage form, and the first prototypes have already been developed. That makes it an attractive prospect for virtually every pharmaceutical company.

    Read

    Commented by Nico Popp on September 26th, 2025 | 07:30 CEST

    AI is conquering increasingly more areas: SAP and Amazon are targeting small and mid-sized businesses, while NetraMark is winning over the biotech industry

    • Biotechnology
    • Biotech
    • AI
    • Technology
    • Innovations

    Will AI become our new god? This question is currently being explored in depth by the German philosopher Markus Gabriel in a well-known German podcast. And although the question may cause unease for many, Gabriel's conclusions are ultimately anything but pessimistic. SAP and Amazon are also looking to the future with optimism: Together with OpenAI, they are now building an AI infrastructure in Germany. The goal: to enable public authorities and companies to use the latest AI tools in a legally compliant manner, without European data leaving the continent. The initiative demonstrates that AI will conquer many more areas in the coming years. One of these areas is medical research. The innovative company NetraMark is using its AI solution to deliver faster results and lower costs for future-focused projects, such as the fight against cancer.

    Read